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Bone turnover biomarkers in COPD patients
randomized to either a regular or
shortened course of corticosteroids: a
substudy of the randomized controlled
CORTICO-COP trial
Pradeesh Sivapalan1,2* , Niklas R. Jørgensen3,4, Alexander G. Mathioudakis5,6, Josefin Eklöf1, Therese Lapperre7,
Charlotte Suppli Ulrik8, Helle F. Andreassen7, Karin Armbruster1, Praleene Sivapalan1, Julie Janner7,
Nina Godtfredsen8, Ulla M. Weinreich9, Thyge L. Nielsen10, Niels Seersholm1, Torgny Wilcke1, Philipp Schuetz11,12,
Tobias W. Klausen13, Kristoffer Marså14, Jørgen Vestbo5,6 and Jens-Ulrik Jensen1,4
Abstract
Background: Long-term treatment with corticosteroids causes loss of bone density, but the effects of using short-
term high-dose systemic-corticosteroid therapy to treat acute exacerbations of chronic obstructive pulmonary
disease (AECOPD) are unclear. Our aim was to determine whether high-dose corticosteroid therapy affected bone
turnover markers (BTMs) to a greater extent compared to low-dose corticosteroid therapy.
Methods: The CORTICO-COP trial (NCT02857842) showed that an eosinophil-guided corticosteroid intervention led
to approximately 60% lower accumulated corticosteroid dose for hospitalized patients with AECOPD (low-dose
group) compared with 5-day standard corticosteroid treatment (high-dose group). We compared the levels of BTMs
C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) in 318
participants during AECOPD and at 1- and 3-month follow-up visits.
Results: CTX decreased and P1NP increased significantly over time in both treatment groups. There were no
significant differences between the groups at 1- or 3-months follow-up for P1NP. A significant drop in CTX was
seen at 3 months (down Δ24% from the baseline, p = 0.017) for the high dose group.
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Conclusion: Short-term, high-dose systemic corticosteroid treatment caused a rapid suppression of biomarkers of
bone resorption. Corticosteroids did not suppress biomarkers of bone formation, regardless of patients receiving
low or high doses of corticosteroids. This therapy was, therefore, harmless in terms of bone safety, in our
prospective series of COPD patients.
Trial registration: ClinicalTrials.gov Identifier: NCT02857842. Submitted August 2nd, 2016.
Keywords: Adverse effects, Bone remodelling, Bone turnover markers, Chronic obstructive pulmonary disease, Corticosteroids
Background
Acute exacerbation of chronic obstructive pulmonary
disease (COPD) can lead to hospitalization and is then
associated with an increased risk of mortality [1]. Rescue
courses of systemic corticosteroids are the standard of
care for more severe acute exacerbations of COPD
(AECOPD). Certain patients with COPD experience fre-
quent exacerbations and are, therefore, exposed to re-
peated courses of corticosteroids for 5–7 days [2].
Patients with COPD are at increased risk of osteoporosis
and fragility fractures as compared to healthy individuals
[3]. Corticosteroids have both anabolic and catabolic ef-
fects on bone. However, overall, corticosteroid therapy
results in decreases in bone formation and bone mineral
density and an increase in bone resorption, as well as
higher risks of fractures and avascular necrosis [4–6].
Corticosteroid-induced osteoporosis is the most com-
mon form of secondary osteoporosis, and the incidence
of fractures in patients receiving long-term corticoster-
oid therapy is as high as 30–50% [7]. For patients under-
going chronic treatment with corticosteroids, the major
mechanism of bone loss is decreased bone formation
due to reductions in the osteoblastic pool and osteoblast
differentiation, especially during the early phase [8]. Cor-
ticosteroid administration may prevent osteoclast devel-
opment from macrophages and limit cytoskeletal
function in a dose-dependent manner [9].
Bone remodelling may be assessed using biochemical
markers that serve as indicators of overall skeletal bone
formation by osteoblasts and bone resorption by osteo-
clasts [10]. Decreased bone formation can be clinically
evaluated by monitoring decreases in the circulating
concentration of the bone formation marker procollagen
type 1 N-terminal propeptide (P1NP). Similarly, bone
degradation can be assessed by monitoring increases in
the bone resorption marker C-terminal telopeptide of
type 1 collagen (CTX) [11].
Many studies have investigated loss of bone density in
patients undergoing chronic treatment with systemic
corticosteroids, but most of these studies involved pa-
tients who had long-term treatment with various doses
of corticosteroids [12, 13]. In contrast, little is known
about the effects on bone metabolism of short-term
therapy with high doses of corticosteroids, such as in the
treatment of AECOPD [14]. Overall, the effects of corti-
costeroids on bone metabolism are not well charac-
terised [15]. Our primary aim of this study was to
explore the adverse effects of corticosteroids on bone by
evaluating the change in bone turnover markers (BTMs)
over time after AECOPD [16].
This randomized controlled trial (RCT) substudy eval-
uated the effects of two different corticosteroid dosing
regimens (“low dose” vs. “high dose”) on BTMs in pa-
tients with AECOPD over a 3-month follow-up period.
Methods
Study design and patients
CORTICOsteroid reduction in COPD (CORTICO-COP)
was a 3-month, investigator-initiated, open-label, random-
ized, non-inferiority trial (clinical trials.gov NCT02857842)
of eosinophil-guided corticosteroid treatment compared
with 5-day standard corticosteroid treatment for patients
with AECOPD [17]. The eosinophil-guided corticosteroid
treatment led to patients receiving an approximately 60%
lower accumulated dose of systemic corticosteroids; thus,
this arm of the trial was named the “low-dose group” in the
current study, whereas the control arm was named the
“high-dose group” (Table 1). We investigated changes in
the levels of BTMs from baseline to 3months follow-up in
these two treatment groups. CTX and P1NP measurements
were recorded from 318 patients during AECOPD and at
1- and 3-month visits. This study was approved by the Eth-
ics Committees of all participating sites (H-15012207) and
the Danish Data Protection Agency (HGH-2015-038 and I-
Suite number 04014).
Biochemical measurements
Serum calcium metabolic parameters, including 25-
hydroxyvitamin D3 (25OHD3), parathyroid hormone
(PTH) and calcium concentrations, were measured
before commencing corticosteroid therapy. Vitamin D
supplements were given to patients with low serum
levels (< 50 nmol/L) of 25OHD3, and calcium supple-
ments were given to patients who had a high risk of
osteoporosis or frequent corticosteroid courses in the
past. CTX and P1NP samples were centrifuged immedi-
ately after collection and stored at − 80 °C until they
were analysed. Fasting blood samples were collected at
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baseline between 7 am and 9 am, after fasting for at least
12 h. It was not always possible to collect 1- and 3-
month fasting blood samples because patients had diffi-
culty attending study visits in the morning. Plasma CTX
levels were measured using the IDS-iSYS CTX Cross-
Laps® assay (Immunodiagnostic Systems, Tyne and
Wear, UK). Plasma P1NP levels were measured using
the IDS-iSYS intact P1NP assay (Immunodiagnostic Sys-
tems). Both assays were chemiluminescence immunoas-
says and were carried out on an iSYS automated
analyser (Immunodiagnostic Systems) according to the
manufacturer’s instructions. None of the samples had
been previously thawed, and all analyses were performed
immediately after thawing the samples. All samples ana-
lysed were from a single batch in each assay. Assay per-
formance was verified using the manufacturer’s control
specimens. The iSYS intermediary precisions expressed
as coefficients of variation were 5.3, 3.4 and 3.5% for
CTX concentrations of 213 ng/L, 869 ng/L and 2113 ng/
L, respectively. The iSYS intermediary precisions were
5.4, 6.5 and 6.1% for P1NP concentrations of 18.96 μg/L,
48.48 μg/L and 122.10 μg/L, respectively. Total 25OHD3
was measured directly using a competitive immunoassay.
Calcium and fasting blood glucose concentrations were
measured using standard methodologies.
Statistical analysis
Data are expressed as medians with interquartile ranges
unless otherwise stated. A p-value < 0.05 was considered
statistically significant. Logarithmic transformation was
used to normalise non-normal distributions. To investi-
gate the sensibility of the log transformation, the
dependent variable was transformed according to the
Box-Cox power transformations. The mixed model used
for calculations were performed using CTX and P1NP
transformed by different lambda values using maximum
likelihood estimation and the log-likelihoods were calcu-
lated depending on lambda value [18]. Furthermore, the
residuals were visually examined using histograms and
qq-plots (Supplementary material, Figure 3S). Con-
strained longitudinal data analysis was used to evaluate
the effects of corticosteroids on baseline levels of P1NP
Table 1 Baseline characteristics
Low-dose group
N = 159
High-dose group
N = 159
Age [years] 75 (69–81) 75 (68–82)
Females, n (%) 86 (54%) 89 (56%)
BMI [kg/m2] 24.2 (20.8–26.6) 23.6 (20.3–27.9)
FEV1% predicted 32 (23.0–39) 30 (23.0–40.5)
Severe exacerbation rate in the previous 12months, mean (95% confidence interval) 0.64 (0.45–0.83) 0.69 (0.44–0.94)
Smokers, n (%) 54 (34%) 50 (31%)
Pack years 45 (30–57) 45 (30–57)
Ca2+ [mmol/L] 1.18 (1.15–1.22) 1.19 (1.15–1.22)
25OHD3 [nmol/L] 76 (48–103) 87 (58–111)
PTH [ρmol/L] 5.4 (4.1–7.6) 5.4 (4.8–7.4)
Fasting blood glucose [mmol/L] 8.1 (7.6–8.6) 8.0 (7.6–8.4)
Leucocytes [× 109/L] 9.8 (7.5–13.5) 9.9 (7.9–13.1)
CRP [mg/L] 22 (8–70) 33 (11–104)
Corticosteroids during hospitalisation [days] 2 (1–3) 5 (5–5)
Cumulative corticosteroid dose during hospitalisation (mg) 121 (113–130) 225 (222–228)
Cumulative corticosteroid dose during 3-month follow-up (mg) 261 (216–301) 421 (353–488)
Inhaled corticosteroid therapy before recruitment 80 (50%) 96 (60%)
Prednisolone prescription 2 weeks before recruitment, n (%) 8 (5%) 12 (8%)
Maintenance of prednisolone treatment (≤ 10mg) daily, n (%) 10 (6%) 7 (4%)
Osteoporosis, n (%) 33 (21%) 26 (16%)
Bisphosphonates within the 12months before inclusion, n (%) 18 (11.3%) 15 (9.4%)
Denosumab within the 12months before inclusion, n (%) 8 (5.0%) 2 (1.3%)
Synthetic human parathyroid hormone within the 12months before inclusion, n (%) 1 (0.6%) 0
Data are expressed as medians (interquartile ranges) unless otherwise stated
Abbreviations: BMI body mass index, FEV1 forced expiratory volume in 1 s, PTH parathyroid hormone, Ca
2+ calcium ion concentration, 25OHD3 25-hydroxyvitamin
D3, CRP C-reactive protein
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and CTX. The advantage of this analysis is that it in-
cludes baseline measurements as dependent variables
[19]. After randomization, the frequency of active treat-
ment for osteoporosis was apparently skewed. Therefore,
we also performed sensitivity analyses, excluding pa-
tients who had received appropriate treatments within
the 12months before inclusion. We also performed post
hoc analyses looking at the linear association between
BTMs and cumulated corticosteroids during the 1- and
3-month follow-up (Supplementary material, Table 1S).
Finally, stratified analysis on inhaled corticosteroid (ICS)
use vs. no ICS use was performed (Supplementary ma-
terial, Table 2S) for the BTMs. Statistical analyses were
performed using SAS software (ver. 9.4; SAS Institute,
Inc., Cary, NC, USA).
Results
Between August 2016 and September 2018, 318 patients
were enrolled in the CORTICO-COP randomized con-
trolled trial; Fig. 1 [17]. There were no significant differ-
ences between the treatment groups in terms of calcium,
25OHD3 or PTH concentrations at the time of recruit-
ment (Table 1). Approximately 50% of the patients in
each group were on ICS treatment (Table 1). The me-
dian times for blood samplings were 06:52 (06:13 - 07:
25), 10:11 (09:00 - 12:03) and 10:30 (9:25 - 12:36) for
AECPOD, 1-month follow up and 3 months follow-up,
respectively. The percentages of patients who had fasting
blood samples were 83.1 % vs. 89.6% (p = 0.11) at the
time of AECOPD, 3.8% vs. 7.0% on day 30 (p = 0.35) and
1.9% vs. 6.3% (p = 0.07) at day 90. (Supplemental mater-
ial Table 3S).
CTX levels declined significantly from baseline to 3
months in both the low-dose and high-dose groups
(Fig. 2). There was no difference in CTX levels between
the treatment groups at 1 month: relative difference at 1
month = 9% (− 8, 28%; p = 0.33). However, at 3 months a
significant drop in CTX was seen for the high dose group:
relative difference = 24% (4, 49%); p = 0.017; Table 2).
Similarly, P1NP increased significantly from baseline
to 3 months in both groups. There was no difference in
P1NP levels between the treatment groups at either time
point: relative difference at 1 month = − 2% (− 14, 10%;
p = 0.70); relative difference at 3 months = − 6% (− 18,
7%; p = 0.33; Table 2, Fig. 2). The P1NP/CTX ratio in-
creased significantly from baseline to 1- and 3-months
follow-up (Tables 2 & 3). However, we only found a dif-
ference between the treatment groups at 3-months
follow-up for the primary analysis (Table 2).
Sensitivity analyses
Excluding 39 patients with known osteoporosis and
those who had taken bisphosphonates, denosumab or
synthetic human parathyroid hormone within the 12
months before inclusion did not change our results for
the BTM levels. The change in CTX levels at 3 months
follow-up was − 14% (− 27, 1%) for the low-dose group
and − 30% (− 40, − 19%) for the high-dose group. The
relative difference between these treatment groups at 3
months was 23% (0, 51%; p = 0.049; Table 3). The in-
crease in P1NP levels at 3 months follow-up was 55%
(38, 73%) for the low-dose group and 60% (44, 78%) for
the high-dose group. The relative difference between
these treatment groups was − 4% (− 17, 12%; p = 0.63;
Table 3).
We also performed stratified analysis, according to
whether patients were on ICS treatment. We observed
an increased CTX value at 3 months in the low dose
group for patients receiving ICS (37.4% (10.2, 71.4%; p =
0.005)) compared to patients not receiving ICS. For
P1NP there was no difference in BTMs between the
groups when stratified for ICS at any time point (supple-
mentary material, Table 2S).
Discussion
In hospitalized patients with AECOPD who, by random
allocation, received either low- or high accumulated dose
of systemic corticosteroid treatment we found that CTX
levels declined and P1NP levels increased between base-
line and 3months in both groups. We did find lower
CTX levels in the high dose group compared to the low
dose groups at 3-month follow up. The increased PINP /
CTX ratio suggests that there is a better balance be-
tween formation and resorption measured by the re-
spective biomarkers during follow-up.
To date no other publications have been devoted to
the assessment of corticosteroid effects on BTMs after
AECOPD. The decreases in CTX levels observed in both
treatment groups over time could be related to reduced
inflammation and recovery after an exacerbation epi-
sode. Studies on patients with rheumatoid arthritis has
shown increased levels of P1NP and CTX in patients
with active disease. Higher concentrations of P1NP and
lower concentrations of CTX were observed in short-
term corticosteroid treated patients, which is consistent
with our results [20]. Furthermore, the CTX levels also
decreased with disease progression [21].
Interestingly, we found that CTX levels began to re-
cover after 1 month in both treatment groups, although
some patients in both groups received additional cor-
ticosteroid courses during the follow-up period. This
trend in serum CTX levels was also observed in other
studies [15, 22] and may reflect the change in dosage or
a skeletal adaptation to corticosteroids.
Our findings are consistent with previous studies, that
showed that 1 week of treatment with 60 mg of daily
prednisone decreased CTX levels, and even lower doses
(10 mg of daily prednisone over 1–2 weeks) decreased
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CTX levels by 10% [23]. Another study investigating the
effects of short-term, high-dose corticosteroid treatment
on BTMs reported a significant decrease in CTX levels
1 month after commencing treatment [22].
Other studies have reported suppression of bone for-
mation in response to long-term treatment with low-
moderate doses of prednisolone, which was reflected by
decreased P1NP levels [15, 22]. We were not able to re-
produce these results in our study. However, P1NP has
not been tested in patients with AECOPD. Thus, our re-
sults could be due to increased remodelling and in-
creased bone formation after AECOPD.
Treatments for osteoporosis interfere with bone remod-
elling, and this is reflected by a decrease in the levels of
bone resorption BTMs and an increase in the levels of
bone formation BTMs [24, 25]. After randomisation, the
frequency of active treatment for osteoporosis was
apparently skewed. Therefore, we also performed sensitiv-
ity analyses, excluding patients who had received relevant
osteoporosis treatments within the 12months before in-
clusion. Overall, these analyses did not change our results
(Table 3).
The strengths of this study included the relatively large
sample size and multi-centre RCT design, published
treatment protocol [16] and the appropriate selection of
biomarkers. Consequently, baseline characteristics in the
high- and low-dose groups were similar. Furthermore,
all the blood measurements were standardised and per-
formed during baseline and follow-up at three central
hospitals.
Although the study has strengths, some limitations de-
serve careful attention. It was nearly impossible to take
fasting blood samples in these severely ill COPD patients
during follow-up since they were too ill to come into the
Fig. 1 CONSORT flowchart
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hospital early in the morning [26, 27], and this variation
may be increased further by food intake [28], which
could have affected our analyses at both 1 and 3months.
However, any such effects on the high- and low-dose
groups are likely to be similar due to randomisation.
The persons who ordered the blood samples at 1 and 3
months, and those who drew the samples, were blinded
to high/low dose group allocation. We compared both
the time at which blood samples were taken, and the
number of fasting blood samples between the two treat-
ment groups and found no differences (Supplemental
material (Supplemental material Table 3S). The fact that
Fig. 2 a CTX and b P1NP measurements for the low- and high-dose groups 3 months after AECOPD. Error bars indicate 95% confidence interval
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we did not perform fasting samples at the later time
points is certainly a limitation; however, since the error
caused by this was randomly distributed between the
two arms, we judged that comparisons between these
two groups are warranted. In addition, although CTX
levels may be affected, PINP levels are less sensitive to
food intake. The acute exacerbations may cause systemic
inflammation, which, in turn, may affect bone
metabolism and our analyses. Furthermore, our results
only examine the short-term effects of systemic cortico-
steroid treatment. For patients who have several
AECOPD episodes in a year, the results may vary.
Some of our patients received vitamin D supplements,
which could also have influenced our results. However,
because this was an RCT, vitamin D supplements were
Table 2 Percentage change in CTX and P1NP levels from baseline (AECOPD) to 1- and 3-month follow-up
Total N = 318 Baseline
(μg/L)
N = 298
1month (difference from
baseline (95% CI))
N = 213
3months (difference from
baseline (95% CI))
N = 193
CTX
Low-dose group
196 −20% (− 30, − 8%); p < 0.0013 − 4% (− 17, 10%); p = 0.55
CTX
High-dose group
196 −26% (− 35, − 16%); p < 0.0001 −23% (− 32, − 12%); p = 0.0001
Relative difference between treatment groupsa 9% (−8, 28%); p = 0.33 24% (4, 49%); p = 0.017
P1NP
Low-dose group
34 60% (47, 75%); p < 0.0001 53% (38, 69%); p < 0.0001
P1NP
High-dose group
34 64% (51, 78%); p < 0.0001 63% (49, 79%); p < 0.0001
Relative difference between treatment groupsa −2% (− 14, 10%); p = 0.70 −6% (− 18, 7%); p = 0.33
P1NP/CTX ratio
Low dose group
0.11 2.18 (1.91–2.49) p < 0.0001 2.11 (1.82; 2.40) p < 0.0001
P1NP/CTX ratio
High dose group
0.11 2.08 (1.81;2.39) p < 0.0001 1.70 (1.46; 1.97) p < 0.0001
Relative difference between treatment groupsa 0.95 (0.81; 1.12) p = 0.56 0.81 (0.67; 0.98) p = 0.029
athe relative difference between groups is calculated as the time–group interaction at the specific visit
Abbreviations: CTX C-terminal telopeptide of type 1 collagen, P1NP procollagen type 1 N-terminal propeptide
Table 3 Percentage change in CTX and P1NP levels from baseline (AECOPD) to 1- and 3-month follow-up excluding patients who
had osteoporosis and those who had taken bisphosphonates, denosumab or synthetic human parathyroid within the 12 months
before inclusion
Total N = 279 Baseline
(μg/L)
N = 264
1month (difference from
baseline (95% CI))
N = 193
3months (difference from
baseline (95% CI))
N = 179
CTX
Low-dose group
257 − 26% (− 36, − 14%);
p = 0.0002
−14% (− 27, 1%);
p = 0.063
CTX
High-dose group
257 −32% (− 40, − 22%);
p < 0.0001
− 30% (− 40, − 19%);
p < 0.0001
Relative difference between treatment groupsa 8% (−10, 31%);
p = 0.40
23% (0, 51%);
p = 0.049
P1NP
Low-dose group
22 65% (49, 83%);
p < 0.0001
55% (38, 73%);
p < 0.0001
P1NP
High-dose group
22 62% (48, 78%);
p < 0.0001
60% (44, 78%);
p < 0.0001
Relative difference between treatment groupsa 2% (−11, 16%);
p = 0.80
−4% (− 17, 12%);
p = 0.63
P1NP/CTX ratio
Low dose group
0.10 2.29 (1.98–2.65)
p < 0.0001
2.20 (1.89; 2.56)
p < 0.0001
P1NP/CTX ratio
High dose group
0.10 2.22 (1.89–2.60)
p < 0.0001
1.80 (1.53; 2.12)
p < 0.0001
Relative difference between treatment groupsa 0.97 (0.81; 1.17)
p = 0.74
0.82 (0.67; 1.00)
p = 0.052
athe relative difference between groups is calculated as the time–group interaction at the specific visit
Abbreviations: CTX C-terminal telopeptide of type 1 collagen, P1NP procollagen type 1 N-terminal propeptide
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given to both treatment groups and would have had lit-
tle impact on our results.
Conclusions
Short-term, high-dose systemic corticosteroid treatment
caused a rapid suppression of bone resorption bio-
markers. Corticosteroids did not suppress bone forma-
tion biomarkers, regardless of patients receiving low or
high doses of corticosteroids. This therapy was, there-
fore, harmless in terms of bone safety, in our prospective
series of patients. Further studies are needed to confirm
our results, owing to the limitation of our study.
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